Actively Recruiting

Phase 3
Age: 18Years - 75Years
All Genders
NCT07036172

Efficacy and Safety of Semaglutide Injection Vs WEGOVY® in Chinese Obese Patients

Led by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Updated on 2025-06-25

460

Participants Needed

1

Research Sites

69 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is a 48-week randomized, open-label, parallel-controlled biosimilar comparison study comparing the efficacy, safety and immunogenicity of the investigational drug and WEGOVY® in patients with obesity. Eligible participants will be screened and randomized to the experimental group and the active comparator group at a ratio of 1:1 , semaglutide injection or WEGOVY® injection will be given once weekly for 44 weeks, following by a safety follow up of 4 weeks. All participants received a lifestyle intervention that involved counselling on diet and physical activity.

CONDITIONS

Official Title

Efficacy and Safety of Semaglutide Injection Vs WEGOVY® in Chinese Obese Patients

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Male or female, aged 18 years and older up to 75 years at consent
  • Body mass index (BMI) of 28 kg/m2 or higher
  • Self-reported body weight change not exceeding 5% within 90 days before screening
Not Eligible

You will not qualify if you...

  • History of type 1 or type 2 diabetes
  • Previous or planned obesity surgery or weight-loss device treatment during the trial
  • History or presence of chronic or acute pancreatitis
  • Personal or first-degree relative history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma
  • History or presence of suspected depression or other mental disorders
  • Patient Health Questionnaire-9 score of 15 or higher at screening
  • Uncontrolled hypertension or recent (within 6 months) serious heart or brain events such as myocardial infarction, stroke, unstable angina hospitalization, or transient ischemic attack
  • History of malignant tumors within 5 years before screening

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Peking University People's Hospital

Beijing, China

Actively Recruiting

Loading map...

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here